Inhibitors for antiviral use
AssigneeOryzon Genomics, S.A.
InventorsJulio Cesar Castro Palomino Laria, Alberto Ortega Munoz, Nathalie Guibourt, Jonathan Alleman Baker
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of potent selective LSD1 inhibitors and LSD1/MAO-B iithibitors for treating or preventing viral infections. Furthermore, the present invention relates to the new use of cyclopropylamine acetamide derivatives or cyclopropylamine derivatives, as defmed herein, for treating or preventing viral infection and treating or preventing reacti - vation of a virus after latency.
Claims18
A method of treating a viral infection, the method comprising administering to a host a therapeutically effective amount of a selective potent LSD1 inhibitor or a LSD1/MAO-B dual inhibitor, or a pharmaceutically acceptable salt thereof.
A method of treating or inhibiting reactivation of a virus after latency in a host, the method comprising administering a therapeutically effective amount of a potent LSD1 inhibitor or a LSD1/MAO-B dual inhibitor, or a pharmaceutically acceptable salt thereof.
A method of treating a viral infection in a mammal that has undergone, is undergoing, or will undergo an organ or tissue transplant, the method comprising administering a therapeutically effective amount of a potent LSD1 inhibitor or a LSD1/MAO-B dual inhibitor, or a pharmaceutically acceptable salt thereof.
5-6. (canceled)
(canceled)
A method of treating HIV in an individual co-infected with a herpes simplex virus 2, the method comprising identifying an individual having HIV and co-infected with herpes simplex virus 2 and administering to the individual a compound selected from the group consisting of a selective potent LSD1 inhibitor, a dual LSD1/MAO-B inhibitor, a cyclopropylacetamide derivative, and a cyclopropylamine derivative.
Dependencies are inferred from the claim text.